how many americans are on glp 1 drugs in 8 is now taking a GLP-1 medication. Yet for patients, the conversation still begins and ends with weight loss. The future of GLP-1 therapy lies in comprehensive protocols As GLP-1 drugs become more
Description
Digital health integration, such as mobile health apps for monitoring and adherence, is further enhancing patient outcomes, while growing awareness about obesity-related health risks is driving demand across both developed and developing regions
Continue all management strategies
The future of pemvidutide (and by extension Altimmune) rests on future trials showing weight reductions that match Wegovy or replicating NASH improvement trends from the Phase 1b (no small feat)
The dual-hormone action often leads to stronger appetite control and faster results compared to traditional GLP-1 medications
